IMV

$3.53
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.21 (+6.33%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell IMV and other stocks, options, and ETFs commission-free!

About IMV

IMV Inc. Common Shares, also called IMV, is a clinical-stage biopharmaceutical company that engages in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The company leverages its delivery platform (DPX) that programs immune cells directly within the human body to produce robust and sustained target killing capabilities. Its drug candidate, DPX-Survivac, is a targeted T cell therapy that has completed multiple phases 1 and 1b trials generating results in late-stage ovarian cancer and relapsed/refractory DLBCL (Diffuse Large B Cell Lymphoma) where it has identified a predictive biomarker. The company was founded by Warwick Kimmins and Brian E. Lowe on May 18, 2007 and is headquartered in Dartmouth, Canada. The listed name for IMV is IMV Inc. Common Shares.

CEO
Frederic Ors
Employees
—
Headquarters
Dartmouth, Nova Scotia
Founded
2007
Market Cap
253.82M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
267.57K
High Today
$3.55
Low Today
$3.37
Open Price
$3.49
Volume
271.25K
52 Week High
$6.82
52 Week Low
$1.35

IMV Earnings

-$0.10
-$0.07
-$0.03
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 16, Pre-Market

You May Also Like

FMAG
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure